Monitoring Blood-Brain Barrier Integrity Following amyloid-beta Immunotherapy 1 Using 2 Gadolinium-enhanced MRI in a PDAPP Mouse Model

Manuscript Number: 

16-0023R2

Author(s): 
Frederique Bard, Ines Blockx, Steven Einstein, Caroline Guglielmetti, Pieter-Jan Guns, Dimitri Roose, Johan Van Audekerke, Annemie Van der Linden, Marleen Verhoye, Wagner Zago

Disclosures

Frederique Bard

  • Equity:
    Currently Employee of Johnson & Johnson and owns stock in the company
    Sponsors:
    Senior Director

Ines Blockx

  • Nothing to Disclose

Steven Einstein

  • Sponsors:
    I am currently a paid contractor working for Janssen R & D. Janssen sponsored the study with the University of Antwerp

Caroline Guglielmetti

  • Nothing to Disclose

Pieter-Jan Guns

  • Nothing to Disclose

Dimitri Roose

  • Nothing to Disclose

Johan Van Audekerke

  • Nothing to Disclose

Annemie Van der Linden

  • Grants
    • Agency: 
      Janssen Alzheimer Immunotherapy R&D
      Dates: 
      2012-2015

Marleen Verhoye

  • Nothing to Disclose

Wagner Zago

  • Equity:
    W.Zago owns Prothena (PRTA), Amazon (AMZN), and Tesla (TSLA) stocks
    Patents/Royalties
    Employment: Prothena Biosciences Inc Patents: -Use of tau to monitor immunotherapy. Patent number: 9272030, 20150118223 -PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY. Publication number: 20120282248, 20090142270 -Treatment of cerebral amyloid angiopathy. Patent number: 8003097